<DOC>
	<DOCNO>NCT00744562</DOCNO>
	<brief_summary>This open-label Phase 1 dose escalation study OMP-21M18 subject previously treat solid tumor remain standard curative therapy therapy demonstrate survival benefit . Up 30 subject enrol 4 center . Subjects assess safety , immunogenicity , pharmacokinetics , biomarkers , efficacy . No formal interim analysis perform . Prior enrollment , subject undergo screen determine study eligibility . Upon enrollment , subject receive weekly intravenous ( IV ) infusions OMP-21M18 9 week . After 9 week treatment , subject assess disease status . If evidence disease progression tumor small , subject may continue receive IV infusion OMP-21M18 every week disease progression . Dose escalation conduct determine maximum tolerate dose ( MTD ) . The dose level OMP 21M18 0.5 , 1.0 , 2.5 , 5 , 10 mg/kg administer IV weekly 9 dos . No dose escalation reduction allow within dose cohort . The dose may administer time day . Three subject treat dose level dose-limiting toxicity ( DLTs ) observe . If 1 3 subject experience DLT , dose level expand 6 subject . If 2 subject experience DLT , subject dose level 3 additional subject add precede dose cohort unless 6 subject already treat dose level . Subjects assess DLTs time first dose 7 day administration 4th dose , prior administration 5th dose ( i.e. , Days 0-28 ) . Dose escalation , appropriate , occur subject cohort complete Day 28 DLT assessment .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study OMP-21M18 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Subjects must histologically confirm malignancy metastatic unresectable remain standard curative therapy therapy demonstrate survival benefit . In addition , subject must tumor least 2 x 2 cm radiographically apparent CT MRI . 2 . Subjects must receive last chemotherapy , biologic , investigational therapy least 4 week prior enrollment , 6 week last regimen include BCNU mitomycin C. 3 . Age &gt; 21 year 4 . ECOG performance status &lt; 2 5 . Life expectancy 3 month 6 . Subjects must normal organ marrow function define : Leukocytes &gt; 3000/mL Absolute neutrophil count &gt; 1000/mL Hemoglobin &gt; 9.0 g/dL Platelets &gt; 100,000/mL Total bilirubin &lt; 1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 X institutional ULN PT PTT within institutional ULN Creatinine &lt; 1.5 X institutional ULN OR Creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal 7 . Women childbearing potential must prior hysterectomy negative serum pregnancy test use adequate contraception prior study entry must agree use adequate contraception study entry least 6 month discontinuation study drug . Men must also agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry study entry least 6 month discontinuation study drug . 1 . Subjects receive investigational agent 2 . Subjects know brain metastasis , uncontrolled seizure disorder , active neurologic disease 3 . History significant allergic reaction attribute humanized human monoclonal antibody therapy 4 . Significant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 5 . Pregnant woman nurse woman 6 . Subjects know HIV infection 7 . Known bleed disorder coagulopathy 8 . Subjects receive heparin , warfarin , similar anticoagulant . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent . 9 . Subjects know clinically significant gastrointestinal disease include , limited , inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Phase 1 ,</keyword>
	<keyword>dose escalation ,</keyword>
	<keyword>histologically</keyword>
	<keyword>confirm</keyword>
	<keyword>malignancy</keyword>
	<keyword>metastatic</keyword>
</DOC>